News & Videos - MOBERG PHARMA AB [CBOE]

Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge PR Newswire STOCKHOLM, June 11, 2024 STOCKHOLM , June 11, 2024 /PRNewswire/ -- Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has today received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million , related to the warrants of series 2023:1 ("TO 2"), from a few external professional investors and the Company's largest...

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America PR Newswire STOCKHOLM, Oct. 6, 2023 STOCKHOLM , Oct. 6, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America . The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S.. Topline results are expected in January 2025...

Moberg Pharma and Padagis sign agreement for MOB-015 in Israel PR Newswire STOCKHOLM, Aug. 4, 2022 STOCKHOLM , Aug. 4, 2022 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories. Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility. Padagis will conduct...

Moberg Pharma enters into collaboration with Allderma for launch in Scandinavia PR Newswire STOCKHOLM, Nov. 8, 2021 STOCKHOLM , Nov. 8, 2021 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has entered into a collaboration with Allderma AB for the launch of MOB-015 (for nail fungus) in Sweden , Norway and Denmark . Allderma is managed by the commercial leaders which were responsible for the successful Nordic launch of Nalox ® , Moberg Pharma's first-generation nail fungus product. In the...

Moberg Pharma's Interim report for July 2019 - June 2020 to be published on August 11 - Invitation to teleconference PR Newswire STOCKHOLM, Aug. 4, 2020 STOCKHOLM , Aug. 4, 2020 /PRNewswire/ -- On August 11 th , 2020, at 08:00 am (CET) , Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - June 2020 . Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date. The teleconference will be hosted by Moberg...

The Board of Directors Exercises Authorizations to Issue and Repurchase C-shares PR Newswire STOCKHOLM, May 19, 2020 STOCKHOLM , May 19, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announced that the board of directors exercises authorizations to issue and repurchase C-shares, and converts C-shares to common shares, to secure the company's commitments under incentive programme. The extraordinary general meeting of Moberg Pharma AB (publ) on April 28, 2020 resolved - for the purpose of...

Bulletin from Moberg Pharma's AGM 2018 PR Newswire STOCKHOLM, May 15, 2018 STOCKHOLM , May 15, 2018 /PRNewswire/ -- Moberg Pharma AB's ("Company") Annual General Meeting took place on Tuesday, May 15th, 2018 in the Company´s premises in Bromma. Adoption of the income statements and the balance sheets The Annual General Meeting (the "Meeting") approved the income statements and the balance sheets for the fiscal year 2017. The Meeting resolved, in accordance with the proposal of the Board of...

Moberg Pharma AB Interim Report January - March 2018 PR Newswire STOCKHOLM, May 8, 2018 STOCKHOLM , May 8, 2018 /PRNewswire/ -- SIGNIFICANT GROWTH FOR ALL KEY BRANDS FIRST QUARTER (JAN- MAR 2018 ) Net revenue SEK 91.5 million (104.6) EBITDA SEK 21.9 million (16.7) EBITDA margin 24% (16) EBITDA for current product portfolio SEK 27.1 million (21.0) Operating profit (EBIT) SEK 12.5 million (6.9) Net profit after tax SEK 2.0 million (-3.0) Diluted earnings per share SEK 0.12 (-0.17) Operating cash...

U.S. Patent Granted for BUPI PR Newswire STOCKHOLM, May 2, 2018 STOCKHOLM , May 2, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. US 9,956,211 which protects BUPI, currently in development for pain due to oral mucositis. This patent should provide protection through to 2032. The U.S. patent covers a method for the treatment of pain due to oral mucositis in cancer patients by locally administering a...

Moberg Pharma Completes Divestment of Balmex® for $4.25 million PR Newswire STOCKHOLM, April 27, 2018 STOCKHOLM , April 27, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the divestment of the Balmex® brand to Randob Labs for a total consideration of $4.25 million plus the inventory value. The divestment results in a capital gain of circa $0.5 million . The brand Balmex®, with a number of products for treating and preventing diaper rash, was acquired from Chattem Inc. in...

Management Change in Moberg Pharma PR Newswire STOCKHOLM, April 19th, 2018 STOCKHOLM , April 19th, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that Kjell Rensfeldt , VP Research and Development, will retire in the fall but remain with the company part-time as Senior Adviser. On October 1st 2018, Kjell Rensfeldt , VP Research and Development, will retire from Moberg Pharma, but remain with the company in a part-time role as Senior Adviser. The process of finding his replacement has...

Moberg Pharma Annual Report 2017 PR Newswire STOCKHOLM, April 10, 2018 STOCKHOLM , April 10, 2018 /PRNewswire/ -- Moberg Pharma´s Annual Report for 2017 has been published and is available on www.mobergpharma.com About this information Moberg Pharma AB is obliged to make this information public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. (CET) on April 10th, 2018 . For more...

The Nomination Committee's Proposal to the Annual General Meeting 2018 PR Newswire STOCKHOLM, March 13, 2018 STOCKHOLM , March 13, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that the company's Nomination Committee has decided to present the following proposal to the Annual General Meeting 2018. The Nomination Committee The Nomination Committee consists of the Chairman Gillis Cullin representing Östersjöstiftelsen and the members Fredrik Persson representing Zimbrine Holding BV,...

Moberg Pharma Divests Balmex® for $4.25 Million PR Newswire STOCKHOLM, Feb. 28, 2018 STOCKHOLM , Feb. 28, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has entered into an agreement with Randob Labs to divest the brand Balmex® for a total consideration of $4.25 million ( 34.6 million SEK ) plus the inventory value at closing. The divestment is expected to result in a capital gain of circa $0.5 million ( 4.4 million SEK ), enabling Moberg Pharma to further focus resources on its larger...

Moberg Pharma AB Year-end Report 2017 STRONG GROWTH FOR KERASAL NAIL INCREASES EBITDA PR Newswire STOCKHOLM, Feb. 13, 2018 STOCKHOLM , Feb. 13, 2018 /PRNewswire/ -- PERIOD (FULL YEAR 2017)* Net revenue SEK 439.0 million (334.3) EBITDA SEK 89.4 million (77.9) EBITDA margin 20% (23) EBITDA for current product portfolio SEK 106.0 million (93.5) Operating profit (EBIT) SEK 51.1 million (62.2) Net profit after tax SEK 11.1 million (32.7) Diluted earnings per share SEK 0.64 (2.25) Operating cash flow...

Moberg Pharma Receives Favorable Outcome From NAD - Main Competitor to Discontinue Current Marketing PR Newswire STOCKHOLM, Jan. 15, 2018 STOCKHOLM , Jan. 15, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) have received a positive outcome from the NAD (National Advertising Division) regarding a challenge filed on Fungi-Nail, the largest U.S. competitor to the Kerasal Nail ® product. NAD recommends the advertiser to discontinue current product packaging and commercials. Moberg Pharma expects...

Moberg Pharma Reorganizes its Commercial Operations PR Newswire STOCKHOLM, Nov. 30th, 2017 STOCKHOLM , Nov. 30th, 2017 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) is reorganizing its sales and marketing operations to better reflect the company's increased focus on the North American market and to maximize global synergies. A global Consumer Health unit will be established to manage Moberg's direct and distributor sales. Jeff Vernimb , currently General Manager North America , has been appointed...